BALTIMORE, Oct. 3, 2016 /PRNewswire/ -- Elixirgen, LLC, a Baltimore-based biotechnology company, today launched Quick-Muscle™ 1.0, a groundbreaking biological reagent that develops skeletal muscle cells from human stem cells in just a few days — a cutting-edge advancement for a laboratory process that previously took a month or longer.
Pre-orders are also being taken for Quick-Neuron™ 1.0, the fastest and most efficient neuron differentiation kit ever available. Quick-Neuron™ 1.0 yields an abundance of neurons in less than one week and will be available in November.
The Quick-Muscle™ 1.0 cocktail allows skeletal muscle cells to be rapidly and efficiently produced from human embryonic stem cells and induced pluripotent stem cells in only four to five days. Quick-Muscle™ 1.0 is the fastest and most effective product on the market. Quick-Muscle™ 1.0 provides fast access to the skeletal muscle cells needed to explore treatments by drug screening or possible cell transplantation therapy for muscle-related diseases such as muscular dystrophy. The possibilities for this innovative technology are endless.
Quick-Muscle™ 1.0 and Quick-Neuron™ 1.0 transform laboratory work. Scientists now have a much more rapid turn-around time, allowing for greater efficiency and larger-scale research.
Elixirgen holds the exclusive license and proprietary technologies for Quick-Muscle™ and other Quick-Tissue™ products.
Elixirgen is a biopharmaceutical company located at the Science + Technology Park at Johns Hopkins. The company specializes in regenerative and rejuvenative medicine, currently developing therapies for chromosome abnormalities such as Down syndrome, telomere diseases, muscular dystrophies, and aging-associated diseases as well as treatments for cell rejuvenation. Elixirgen is focused on curing humanity's ailments through stem cell biology.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-quick-tissue-kits-revolutionize-skeletal-muscle-and-neuron-differentiation-300336723.html
SOURCE Elixirgen, LLC